EA201591581A1 - Способы лечения псориаза при помощи анти-il-23 антитела - Google Patents

Способы лечения псориаза при помощи анти-il-23 антитела

Info

Publication number
EA201591581A1
EA201591581A1 EA201591581A EA201591581A EA201591581A1 EA 201591581 A1 EA201591581 A1 EA 201591581A1 EA 201591581 A EA201591581 A EA 201591581A EA 201591581 A EA201591581 A EA 201591581A EA 201591581 A1 EA201591581 A1 EA 201591581A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
methods
dose
treating psoriasis
psoriasis
Prior art date
Application number
EA201591581A
Other languages
English (en)
Russian (ru)
Inventor
Джон П. Гиббс
Уэйен Тсуцзи
Вэй-Цзянь Пань
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591581(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA201591581A1 publication Critical patent/EA201591581A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
EA201591581A 2013-03-15 2014-02-25 Способы лечения псориаза при помощи анти-il-23 антитела EA201591581A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15
PCT/US2014/018293 WO2014149425A1 (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Publications (1)

Publication Number Publication Date
EA201591581A1 true EA201591581A1 (ru) 2016-01-29

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591581A EA201591581A1 (ru) 2013-03-15 2014-02-25 Способы лечения псориаза при помощи анти-il-23 антитела

Country Status (17)

Country Link
US (3) US20160060337A1 (https=)
EP (2) EP3689369A1 (https=)
JP (4) JP2016517408A (https=)
KR (1) KR20150128858A (https=)
CN (1) CN105209064A (https=)
AP (1) AP2015008803A0 (https=)
AU (3) AU2014238148A1 (https=)
CA (1) CA2906382A1 (https=)
CL (1) CL2015002723A1 (https=)
CR (1) CR20150572A (https=)
EA (1) EA201591581A1 (https=)
HK (1) HK1219425A1 (https=)
IL (2) IL241342A0 (https=)
PH (2) PH12015502129A1 (https=)
SG (2) SG11201507482UA (https=)
TN (1) TN2015000403A1 (https=)
WO (1) WO2014149425A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) * 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
JP6728392B2 (ja) * 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
US20200025776A1 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
CA3118964A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-tigit antibody for treatment of cancer
JP2022526493A (ja) * 2019-03-18 2022-05-25 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ１２／ｉｌ２３抗体を用いた小児被験者の乾癬の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
DE602006015830D1 (de) 2005-08-25 2010-09-09 Lilly Co Eli Anti-il-23-antikörper
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
PT1931710T (pt) 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
CN101389769A (zh) * 2005-12-28 2009-03-18 森托科尔公司 用于评价和治疗银屑病及相关疾病的标记与方法
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
ES2708988T3 (es) 2007-02-23 2019-04-12 Merck Sharp & Dohme Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009117289A2 (en) * 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
EP2301119B1 (en) 2008-06-30 2015-05-13 Black & Decker, Inc. Cord protector for power tools
EP2331078B1 (en) 2008-08-27 2012-09-19 Merck Sharp & Dohme Corp. Lyophilized formulations of engineered anti-il-23p19 antibodies
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
US20120264917A1 (en) 2009-05-27 2012-10-18 Ablynx N.V. Biparatopic protein constructs directed against il-23
SG179135A1 (en) * 2009-09-14 2012-05-30 Abbott Lab Methods for treating psoriasis
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PH12012501364A1 (en) 2010-01-15 2012-10-22 Amgen K A Inc Antibody formulation and therapeutic regimens
WO2012009760A1 (en) 2010-07-20 2012-01-26 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
CN103813804A (zh) * 2010-10-06 2014-05-21 Abbvie公司 用于治疗银屑病的方法
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.

Also Published As

Publication number Publication date
CL2015002723A1 (es) 2016-03-28
HK1219425A1 (zh) 2017-04-07
PH12019502700A1 (en) 2020-12-07
CN105209064A (zh) 2015-12-30
AU2014238148A1 (en) 2015-10-08
IL241342A0 (en) 2015-11-30
AP2015008803A0 (en) 2015-10-31
CA2906382A1 (en) 2014-09-25
SG11201507482UA (en) 2015-10-29
EP2968488A1 (en) 2016-01-20
AU2019200206A1 (en) 2019-01-31
JP2023011815A (ja) 2023-01-24
JP2016517408A (ja) 2016-06-16
US20160060337A1 (en) 2016-03-03
CR20150572A (es) 2016-04-25
SG10201804954UA (en) 2018-07-30
US20200277368A1 (en) 2020-09-03
TN2015000403A1 (en) 2017-01-03
JP2021102644A (ja) 2021-07-15
AU2020270495A1 (en) 2020-12-17
US20220135668A1 (en) 2022-05-05
JP2020063237A (ja) 2020-04-23
KR20150128858A (ko) 2015-11-18
EP3689369A1 (en) 2020-08-05
PH12015502129A1 (en) 2016-01-25
IL275093A (en) 2020-07-30
WO2014149425A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
EA201591581A1 (ru) Способы лечения псориаза при помощи анти-il-23 антитела
EA201591579A1 (ru) Способы лечения болезни крона при помощи анти-il-23 антитела
CY1119435T1 (el) Σκευασμα για αντισωμα εναντι- αλφα4βητα7
EA201890204A1 (ru) Антибактериальные соединения
BR112017018954A2 (pt) uso de forma mutante de proteína ras e método para tratar câncer
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201990043A1 (ru) Антибактериальные соединения
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
BR112018000212A2 (pt) uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer
EA201790334A1 (ru) Конъюгаты анти-cdh6 антитела с лекарственным средством
MX374785B (es) Anticuerpos anti-fgfr2iiib afucosilados.
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
JO3564B1 (ar) ببتيدات وتركيبات لعلاج ضرر المفاصل
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MY182134A (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and uses thereof
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use